Amivantamab and Lazertinib in EGFR-mutated NSCLC: Rick of Thromboembolism - Venous ThromboEmbolism

Amivantamab and Lazertinib in EGFR-mutated NSCLC: Rick of Thromboembolism - Venous ThromboEmbolism - ALERT-VTE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060483

Enrollment

350

Registered

2026-01-30

Start date

2026-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Venous Thromboembolism (Pulmonary embolism and deep vein thrombosis)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients aged 20 years or older with EGFR-mutated NSCLC who meet one of the following conditions: 1. Initiating combination therapy with amivantamab and lazertinib. 2. Initiating monotherapy with either amivantamab or lazertinib. - Patients who have provided written informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Incidence of venous thromboembolism and bleeding from treatment initiation to the end of the follow-up period	—

Countries

Japan

Contacts

Public ContactYuto Miura

Kyoto University Graduate School of Medicine Department of Cardiovascular Medicine

myuto_knzw@kuhp.kyoto-u.ac.jp075-751-4255

Outcome results